Clinical Trial Update: Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pegcetacoplan (Syfovre) in a prefilled syringe for geographic atrophy secondary to age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• SYFOVRE (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | Status: COMPLETED